Sanofi stops development of Nurix-partnered immune drug
BioPharma DiveDelilah AlvaradoNovember 4, 2026
The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a tough-to-reach protein called STAT6.